Patrick Smith Sells 10,000 Shares of Axon Enterprise (NASDAQ:AXON) Stock

Posted by Geri Gentry on Sep 10th, 2026

Axon Enterprise, Inc (NASDAQ:AXON – Get Free Report) CEO Patrick Smith sold 10,000 shares of Axon Enterprise stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $508.99, for a total transaction of $5,089,900.00. Following the sale, the chief executive officer owned 3,118,012 shares of the company’s stock, valued at approximately $1,587,036,927.88. This represents a 0.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Axon Enterprise Trading Down 2.3%

Shares of AXON stock traded down $11.15 during trading hours on Thursday, hitting $478.85. The company had a trading volume of 933,953 shares, compared to its average volume of 1,044,202. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.15 and a quick ratio of 1.80. The stock has a market capitalization of $38.90 billion, a PE ratio of 198.69, a price-to-earnings-growth ratio of 9.86 and a beta of 1.40. The company’s fifty day moving average is $566.39 and its 200 day moving average is $488.10. Axon Enterprise, Inc has a fifty-two week low of $339.01 and a fifty-two week high of $792.16.

Axon Enterprise (NASDAQ:AXON – Get Free Report) last posted its earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 earnings per share for the quarter, beating the consensus estimate of $1.84 by $0.04. The firm had revenue of $904.39 million during the quarter, compared to the consensus estimate of $876.42 million. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. The firm’s revenue for the quarter was up 35.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.12 EPS. Research analysts expect that Axon Enterprise, Inc will post 2.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Creative Financial Designs Inc. ADV purchased a new stake in Axon Enterprise during the 4th quarter worth about $28,000. Keating Financial Advisory Services Inc. purchased a new position in shares of Axon Enterprise in the 2nd quarter valued at about $31,000. AlphaCentric Advisors LLC purchased a new position in shares of Axon Enterprise in the 4th quarter valued at about $34,000. Darwin Wealth Management LLC acquired a new position in shares of Axon Enterprise during the second quarter worth about $37,000. Finally, Washington Trust Advisors Inc. grew its position in shares of Axon Enterprise by 1,300.0% during the second quarter. Washington Trust Advisors Inc. now owns 70 shares of the biotechnology company’s stock worth $39,000 after buying an additional 65 shares in the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

AXON has been the topic of several research analyst reports. The Goldman Sachs Group reiterated a “buy” rating and issued a $715.00 price objective on shares of Axon Enterprise in a report on Thursday, August 6th. UBS Group raised their target price on Axon Enterprise from $440.00 to $600.00 and gave the company a “neutral” rating in a report on Thursday, August 6th. Argus lifted their target price on Axon Enterprise from $460.00 to $600.00 and gave the company a “buy” rating in a research report on Thursday, September 3rd. Citizens Jmp reiterated a “market outperform” rating and set a $700.00 price target on shares of Axon Enterprise in a research note on Thursday, June 25th. Finally, Royal Bank Of Canada reissued an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, July 21st. Fourteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Axon Enterprise currently has an average rating of “Moderate Buy” and an average price target of $721.57.

Get Our Latest Research Report on Axon Enterprise

About Axon Enterprise

(Get Free Report)

Axon Enterprise, Inc develops technology and equipment for law enforcement, public safety and other government agencies. Its product portfolio includes TASER energy weapons, body-worn cameras, in-car cameras and related connected devices designed to support safer interactions, improve transparency and collect operational data.

The company also provides cloud-based software for managing digital evidence, conducting investigations, overseeing records and workflows, coordinating dispatch and supporting real-time public safety operations.